Tadalafil
Founded in 2017, Sigma Chemical Co., Ltd. supplies over 100 countries with high-quality chemicals. We are dedicated to safety, innovation, and global cooperation.
Product Description
Tadalafil (brand name Cialis) is a phosphodiesterase type 5 (PDE5) inhibitor based on a tetrahydro-β-carboline scaffold, and its (6R,12aR) stereoconfiguration is crucial for highly selective inhibition of the PDE5 enzyme. By competitively inhibiting cGMP hydrolysis, tadalafil increases intracavernous cGMP concentration, thus relaxing blood vessels. Clinically, it is primarily used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is important to note that tadalafil is strictly contraindicated with nitrate medications due to the risk of synergistic hypotension, and because of its long-lasting effects (up to 36 hours) and potential side effects (such as headache and back pain), it should only be used under professional guidance.
Regulatory Status & Guidelines
- Approved by the FDA and other agencies for ED, BPH, and PAH.
- For PAH, guidelines recommend it as monotherapy or in combination (e.g., with ambrisentan) for WHO-FC II/III patients.
Synthesis Methods
Chemical Synthesis
The synthesis of Tadalafil involves a multi-step process, with the Pictet-Spengler reaction as a key step to construct its complex tetrahydro-β-carboline core structure. The synthesis typically starts from chiral precursors like L-tryptophan methyl ester to ensure the correct (6R, 12aR) stereochemistry, which is crucial for its biological activity.
Uses and Applications
Approved Therapeutic Uses
- Erectile Dysfunction (ED): Its initial and most common use, with a long duration of action.
- Symptoms of Benign Prostatic Hyperplasia (BPH): Relaxes smooth muscle in the prostate and bladder.
- Pulmonary Arterial Hypertension (PAH): Used to promote pulmonary vasodilation (e.g., once-daily dosing at 40 mg).
Investigational & Emerging Uses
- Fetal Growth Restriction (FGR): Shows promise in improving placental perfusion and prolonging pregnancy, as studied in the TADAFER trials. It appears to act primarily on the maternal side with limited placental transfer.
- Cerebral Small Vessel Disease (CSVD): Investigated for improving cerebrovascular reactivity and reducing white matter hyperintensity burden, as in the ETLAS-2 trial.
- Peyronie's Disease: Low-dose daily use may reduce penile curvature progression in the acute phase.
- Heart Failure with Preserved Ejection Fraction (HFpEF) & Pulmonary Hypertension (PH): Evaluated for combined post- and pre-capillary PH (CpcPH), though the PASSION trial did not show benefit and raised safety concerns.
- Neuroprotection: Preclinical data in FGR mouse models suggest potential neuroprotective effects in offspring.
- Potential Broader Benefits: Large observational studies associate its use with reduced risks of all-cause mortality, cardiovascular disease (myocardial infarction, stroke), and dementia in men with ED or lower urinary tract symptoms (LUTS).
Properties and Characteristics
Mechanism of Action: Inhibits the degradation of cyclic guanosine monophosphate (cGMP) by PDE5, enhancing the nitric oxide (NO)-cGMP signaling pathway. This leads to vascular smooth muscle relaxation and vasodilation in target tissues (corpus cavernosum, pulmonary vasculature, placental vasculature).
Pharmacokinetic & Pharmacodynamic Features
- Long Half-life: (~17.5 hours), allowing for once-daily dosing in some indications.
- High Selectivity for PDE5: Compared to other PDE isoforms (e.g., PDE11), contributing to its side effect profile.
- Limited Placental Transfer: Preclinical data (mouse models) and pharmacological studies suggest lower transfer across the placental barrier compared to sildenafil, possibly due to efflux transporters like BCRP.
- Onset of Action: More rapid than sildenafil.
- Food Interaction: Negligible effect on bioavailability.
Key Differentiators from Sildenafil: Longer half-life, higher PDE5 selectivity, different placental transport profile, and potentially distinct side effect and safety profiles (e.g., no increased risk of neonatal persistent pulmonary hypertension (PPHN) was observed in TADAFER II, unlike with sildenafil in the STRIDER trial).
Safety and Handling
Common Side Effects: Headache, facial flushing, nasal congestion, dyspepsia, back pain, myalgia, dizziness. These are generally mild and dose-dependent.
Serious Risks & Contraindications:
- Absolute Contraindication: Concomitant use with nitrates (e.g., nitroglycerin) or nitric oxide donors due to risk of severe, life-threatening hypotension.
- Cardiovascular Risk: Use with caution in patients with cardiovascular disease. The PASSION trial reported a signal of increased all-cause mortality in HFpEF patients with CpcPH, though causality was not proven.
- Special Populations:
- Pregnancy (for FGR): Clinical trials (TADAFER II) indicate it may be safe for the fetus and neonate, with no drug-related severe adverse maternal events observed. However, it remains investigational for this use.
- Gender Differences: The ETLAS-2 trial noted significantly lower tolerability and higher discontinuation rates due to side effects (e.g., headache, muscle pain) in female participants.
Drug Interactions: Primarily metabolized by CYP3A4. Strong inhibitors (e.g., ketoconazole, ritonavir) can increase tadalafil exposure, while inducers (e.g., rifampin) can decrease it.
Handling in Research: In clinical trials, it is often encapsulated with matching placebos to maintain blinding. Stability and consistent supply are critical for trial integrity.